Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • DOP junks Geltec plea...

    DOP junks Geltec plea against NPPA decision on retail price of Ibuprofen Soft Gelatin Capsules

    Farhat NasimWritten by Farhat Nasim Published On 2019-07-28T11:30:35+05:30  |  Updated On 17 Aug 2021 11:36 AM IST

    New Delhi: Through a recent decision, the Department of Pharmaceuticals (DOP) has rejected the review application filed by Geltec Private Limited against National Pharmaceutical Pricing Authority (NPPA) for price fixation of its formulations "Ibuprofen 400mg Soft Gelatin Capsules and Ibuprofen 200mg Soft Gelatin Capsules".




    Ibuprofen is used to relieve pain from various conditions such as headache, dental pain, menstrual cramps, muscle aches, or arthritis. It is also used to reduce fever and to relieve minor aches and pain due to the common cold or flu. The formulation is a nonsteroidal anti-inflammatory drug (NSAID).


    Challenging NPPA's decision, Geltec applied for separate retail prices for its formulations Ibuprofen 400mg Soft Gelatin Capsules and Ibuprofen 200mg Soft Gelatin Capsules under the provisions of Para 5 and 15 of the DPCO 2013.


    Also Read: DOP rejects Mylan review application for revising the retail price of Hepatitis B, HIV drug


    However, the NPPA did not fix the retail prices of the said formulations and directed the company to follow the ceiling price of Ibuprofen 400mg and 200mg hard gelatin capsules notified in 2018.


    Having been aggrieved by the response of the NPPA, Geltec submitted the review application to the department for separate retail prices for its formulations. As per the para 31 of the DPCO, any person aggrieved by any notification issued or order made under paragraph 4, 5 and 6 of the DPCO, may apply to the Government for a review of the notification or order.


    In the instant case, the petitioner, GELTEC filed a review against the NPPA which was simply a reply to the company against its Form I application. Noting this, DOP rejected the company's plea


    "Filing of a review application against a letter is not as per the provisions laid down in the DPCO. Hence, the review application is liable to be rejected," reads the order.


    Subsequently, DOP rejected the plea filed by Geltec against NPPA.


    Also Read: Refix ceiling price of Zydus Healthcare Tiotropium Inhalation: DoP directs NPPA

    arthritiscommon colddental painDepartment of PharmaceuticalsDOPDPCOfeverflugelatin capsulesGeltecGeltec petitionheadacheibuprofenIbuprofen Soft Gelatin Capsulemenstrual crampsmuscle achesNPPApharmapharma newspharma news indiareview order

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok